Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
4
×
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
clinical trials
drugs
rna interference
aminolevulinic acid
fda
givosiran
national top stories
onpattro
patisiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
biotech
boehringer ingelheim
deals
dicerna pharmaceuticals
eli lilly
european medicines agency
harvard pilgrim health care
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
institute for clinical and economic review
johnson & johnson
neurodegenerative diseases
new york blog main
new york top stories
What
interference
4
×
rna
rnai
4
×
alnylam
drug
medicine
ago
fda
pharmaceuticals
second
seek
speedy
abandoning
approval
approves
baggage
cells
cleared
companies
cuts
data
deal
development
dicerna
ema
employ
europe
far
follows
free
gene
gets
harmful
hits
indicated
long
make
market
medicines
method
Language
Current search:
interference
×
rnai
×
" boston blog main "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug